SOPs for BA-BE Studies V 2.0

To define the procedures and staffing responsibilities required to manage study subjects during weekends and public holidays, ensuring uninterrupted monitoring, subject comfort, and protocol compliance throughout the BA/BE study period.
Click to read the full article.

To define a standardized and compliant method for identifying, recording, evaluating, and reporting incidents that occur during the conduct of clinical trials in BA/BE studies, ensuring corrective and preventive actions and adherence to GCP and regulatory guidelines.
Click to read the full article.

To define a structured procedure for identifying, mitigating, and managing risks associated with gender-specific physiological and pharmacokinetic variations in subjects participating in BA/BE studies.
Click to read the full article.

To establish a standardized procedure for receiving, storing, monitoring, and documenting clinical trial materials (CTM) including investigational medicinal products (IMP), reference products, and ancillary materials at the BA/BE site in compliance with GCP and regulatory requirements.
Click to read the full article.

To ensure clear definition, documentation, communication, and adherence to roles and responsibilities of all personnel involved in BA/BE clinical trials, thereby promoting accountability, reducing errors, and supporting GCP compliance.
Click to read the full article.

To establish a systematic approach for the ongoing medical surveillance of healthy volunteers participating in BA/BE studies to monitor their health status, ensure early detection of adverse events, and support protocol compliance.
Click to read the full article.

To define a structured and consistent approach for identifying, documenting, classifying, reporting, and escalating protocol deviations (PDs) encountered during the conduct of bioavailability/bioequivalence (BA/BE) studies to ensure transparency, subject safety, and regulatory compliance.
Click to read the full article.

To establish a standardized approach for minimizing noise and controlling environmental disturbances within the clinical facility during the conduct of BA/BE studies, in order to maintain volunteer comfort, reduce bias, and ensure the integrity of collected clinical and bioanalytical data.
Click to read the full article.

To define the standardized process for identifying, documenting, and reporting adverse events (AEs) and serious adverse events (SAEs) to the Sponsor and Ethics Committee (EC) in compliance with GCP, Schedule Y, and applicable regulatory guidelines during BA/BE studies.
Click to read the full article.

To define a structured protocol for identifying, managing, and documenting medical emergencies during the conduct of BA/BE studies at the clinical site to ensure subject safety, rapid intervention, and regulatory compliance.
Click to read the full article.